1. Tozinameran (BNT162b2) COVID-19 vaccine is the first to hit the U.S. market
A vial of the BNT162b2 COVID-19 vaccine. Image courtesy of Lisa Ferdinando from the Department of Defense.
Developers: Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX).
Description: Proposed indication is the prevention of COVID-19 in individuals 16 years of age and older. The vaccine uses an mRNA platform to targets the P2-mutated full spike protein of the SARS-COV-2 virus. The final analysis from a Phase 3 trial suggests that the vaccine is 95% effective at preventing COVID-19 symptoms and is generally well tolerated.
The vaccine’s current formulation must be stored between –80 and –60° C. Pfizer is currently evaluating whether the vaccine is stable at 2 to 8°C. The company is working on a new formulation that could be stable at room temperature.
Development status: Tozinameran became the first COVID-19 vaccine to win emergency use authorization from the FDA on Dec. 11. Pfizer plans to file a Biologics License Application (BLA) with FDA and anticipates full regulatory approval in 2021.
Pfizer intends to produce 1.3 billion doses of the vaccine by the end of 2021.
Tell Us What You Think!